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Abstract
Background
Continuing tuberculosis control with current approaches is unlikely to reach the World
Health Organization’s objective to eliminate TB by 2035. Innovative interventions such as
unmanned aerial vehicles (or drones) and digital adherence monitoring technologies have
the potential to enhance patient-centric quality tuberculosis care and help challenged
National Tuberculosis Programs leapfrog over the impediments of conventional Directly
Observed Therapy (DOTS) implementation. A bundle of innovative interventions referred to
for its delivery technology as the Drone Observed Therapy System (DrOTS) was imple-
mented in remote Madagascar. Given the potentially increased cost these interventions rep-
resent for health systems, a cost-effectiveness analysis was indicated.
Methods
A decision analysis model was created to calculate the incremental cost-effectiveness of the
DrOTS strategy compared to DOTS, the standard of care, in a study population of 200,000
inhabitants in rural Madagascar with tuberculosis disease prevalence of 250/100,000. A
mixed top-down and bottom-up costing approach was used to identify costs associated with
both models, and net costs were calculated accounting for resulting TB treatment costs. Net
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cost per disability-adjusted life years averted was calculated. Sensitivity analyses were per-
formed for key input variables to identify main drivers of health and cost outcomes, and
cost-effectiveness.
Findings
Net cost per TB patient identified within DOTS and DrOTS were, respectively, $282 and
$1,172. The incremental cost per additional TB patient diagnosed in DrOTS was $2,631 and
the incremental cost-effectiveness ratio of DrOTS compared to DOTS was $177 per DALY
averted. Analyses suggest that integrating drones with interventions ensuring highly sensi-
tive laboratory testing and high treatment adherence optimizes cost-effectiveness.
Conclusion
Innovative technology packages including drones, digital adherence monitoring technolo-
gies, and molecular diagnostics for TB case finding and retention within the cascade of care
can be cost effective. Their integration with other interventions within health systems may
further lower costs and support access to universal health coverage.
Introduction
Tuberculosis (TB) is the leading infectious disease killer globally, surpassing HIV/AIDS and
malaria, with 10 million new cases estimated in 2019 [1]. Among those, 3 million cases are
classified as “missing”, meaning they are undiagnosed or unreported and thus contributing to
the continued epidemic. Innovative case finding, and control interventions are needed as con-
ventional approaches alone are predicted to fail to meet the World Health Organization
(WHO) End TB Strategy’s objectives including that of eliminating TB by 2035 [2, 3]. In 2019,
the Madagascar National TB Control Program (NTP) notified 34,191 TB cases. This repre-
sented only 56% of the country’s annual incident cases as estimated by WHO [4].
Some of the biggest challenges low- and middle-income countries (LMIC) face for quality
TB care include program underfunding, limited financial resources absorption capacity, low
geographic coverage of centralized healthcare systems, paucity of trained healthcare personnel,
weak diagnostic laboratory infrastructure, remoteness of rural communities, and limited
transportation infrastructure that is sometimes exacerbated by difficult weather conditions [5–
7]. To overcome some of these impediments, innovative technologies such as drones to facili-
tate clinical sample movement and strengthen healthcare supply chain were shown to have
added value in specific settings [8–10]. Digital adherence monitoring technologies also repre-
sent a promising approach to improve and remotely monitor TB treatment adherence [11].
The use of drones in global health settings has rapidly evolved in the last years. As drone
technology applications continue to expand beyond the military and recreational sectors, it is
foreseen that drones will have a significant role to play for healthcare delivery in high- and
low-income countries where either urgency, such as in the case of organ transplantation or
cardiac arrest, or transportation complexity, such as in the case of last-mile delivery for
enclaved population will justify their use [12, 13]. Drones also have the potential to revolution-
ize healthcare supply chain systems, facilitate surveillance in geographically challenging
regions and support emergency response in face of life-threatening patient conditions or natu-
ral disasters [8, 14–16]. Despite the roll out of multiple drone pilot projects, especially in sub-
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Saharan Africa, very little data is available on the health impact and costs of drone-supported
interventions prior to this study [8].
In August 2017, the Drone Observed Therapy System (DrOTS) project was launched in Ifa-
nadiana district, in southeastern Madagascar. DrOTS is a bundle of innovative interventions
supporting community-based TB case finding including (i) drones to deliver sputum samples
and TB medication between rural communities and diagnostics and treatment facilities; (ii)
GeneXpert™ MTB/RIF (Cepheid, Sunnyvale CA USA) molecular platform to increase sensitiv-
ity and specificity of TB diagnosis and; (iii) WHO endorsed evriMED™ (Wisepill, Somerset
West, South Africa) digital adherence monitoring technology to remotely assess TB treatment
adherence by monitoring daily opening of an electronic pill box [17, 18]. In the context of iso-
lated remote populations, this technology-supported model of TB care potentially allows for
increased case finding and notification, faster diagnosis, and increased patient retention at
every step of the cascade of care by favoring a patient-centric and community-based approach.
The global market for innovations like drones and evriMED™ devices in healthcare is rap-
idly developing and technology-associated costs are decreasing. Initially restricted to product
developers and academia, the use of such technologies is now democratized to non-govern-
mental organizations (NGO) and the public health sector allowing for larger scale-up [15, 19].
For NTPs in LMICs with limited financial and human resources, detailed economic evalua-
tions of new programmatic strategies including such technologies are indicated to inform
affordability and resource allocation priorities.
We present a cost-effectiveness analysis (CEA) of DrOTS compared to Directly Observed
Therapy Short course (DOTS) from a healthcare system perspective [20]. DOTS is accepted as
standard of care for TB treatment and adherence monitoring in most LMICs, including Mada-
gascar. This CEA model sets a baseline for the economic evaluation of the use of drones and
other innovative technologies for TB control.
Materials and methods
In this CEA study, we use a decision analysis model to calculate the incremental cost-effective-
ness of the DrOTS strategy compared to DOTS. This CEA study was conducted according to
recommended methods and reporting for health care sector perspective CEA and a reporting
checklist for cost-effectiveness analyses is provided as supplementary materials [21]. The over-
all DrOTS study, including the cost-effectiveness analysis, received ethical approval from both
the Stony Brook University Internal Review Board (CORIHS# 2017-4056-F) and the “Comite´
d’E´thique de la Recherche Biome´dicale” from the Ministry of Public Health in Madagascar
(073-MSANP/CERBM).
Study area and target population
Ifanadiana, a geographically remote district in the southeastern part of Madagascar, served as
the use case typifying remote, impoverished and high TB burden areas. In this district, TB con-
trol activities are coordinated from a centralized diagnosis and treatment center (CDT) where
a laboratory and pharmacy provide services to a population approximating 200,000 inhabi-
tants. Twelve additional basic health care facilities in the district can supervise TB treatment
administration, but initial diagnosis of TB is only performed in the CDT. The district is
divided by a single paved road and access to the CDT from rural communities can require
multiple days of walking which represents a significant barrier to access to care [22]. Madagas-
car’s national TB guidelines recommend morning sputum smear microscopy on three conse-
cutive days for initial TB diagnosis [23]. These can be prepared by nurses in the basic health
care facilities and carried to the CDT by volunteer community health workers (CHW). In
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2018, 175 TB cases were reported in Ifanadiana, what corresponds to a notification rate of 88/
100,000, less than one third of the county’s average rate. The DOTS completion rate in the dis-
trict was locally assessed to be 60% whilst the national successful treatment rate was reported
to be 82% [24].
Modeled strategies
The incremental cost-effectiveness ratio (ICER) measures the economic value of one interven-
tion or strategy compared to another [25]. In our CEA, we compare conventional DOTS as
per national TB guidelines, with DrOTS (Fig 1). For both models, primary field data was col-
lected simultaneously in August 2017. For both modeled strategies, the total number of tested,
diagnosed and treated individuals are presented in the results section.
DOTS. DOTS (Fig 1) relies on passive case finding, a strategy where symptomatic patients
self-report to CHW or healthcare facilities. If appropriately tested and diagnosed with TB
using smear microscopy, patients are initiated on therapy. DOTS requires patients to visit the
treatment center on a daily basis for direct observation of medication intake during the initial
2 months of treatment. In cases of severe disease or incapacity to walk the necessary distance
on a daily basis, patients should relocate close to the healthcare center during this period. Drug
dispensing thereafter occurs monthly for the 4-months continuation phase of treatment
Fig 1. Modeled TB care strategies. DOTS; Directly Observed Therapy, DrOTS; Drone Observed Therapy System, GeneXpert™; GeneXpert™ MTB/RIF TB molecular
testing platform, evriMED™; Digital adherence monitoring technology.
https://doi.org/10.1371/journal.pone.0235572.g001
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during which patients take medication back to their household. Adherence monitoring is
based on pill count at the end of each month and therapy success is assessed through control
sputum smear microscopy after 2, 5 and 6 months of treatment.
DrOTS. In DrOTS (Fig 1), active case finding, and innovative technologies are combined
to facilitate community-based TB control. CHW perform bi-annual community outreach activ-
ities and identify symptomatic individuals and confirmed TB cases household contacts at village
level. CHW then signal the health facility, via cell phone or global positioning system (GPS)
tracker communication, and a drone travels from the CDT to the targeted remote community.
One sputum sample from a person with suspected TB is flown back to the CDT where GeneX-
pert™ MTB/RIF testing is performed. In case of confirmed diagnosis, one month of anti-TB
medication in an evriMED™ device is flown back to the patient. CHW equipped with tracker
communication system assist this process and ensure all patients are provided with the appro-
priate medication at the right time. For modeling purposes, the impact of drones is captured by
directly increasing the probability of TB suspects accessing TB diagnostic services and being
tested for TB. Despite their presence in communities in DOTS, CHW don’t have the ability to
overcome the transportation challenges related to ensuring access to TB diagnostic services for
all TB suspects. DrOTS, medication is dispensed this way on a monthly basis requiring a total of
7 round-trip flights for a full course of therapy. As with DOTS, sputum smear microscopy is
used as a surrogate marker for treatment adherence and efficacy at months 2, 5 and 6. Activities
are coordinated by the laboratory technician at the CDT and the drone technician and drones
are stored and maintained at the CDT. An hybrid quad-copter and fixed-wing drone performs
vertical landing and take-off at predetermined GPS coordinates allowing semi-automated bi-
directional transport of 2.2 kg of cargo on a distance of 120 km [16]. Sample transport proce-
dures adhere to WHO biosecurity guidelines for infectious substances transportation [26].
Flight trajectory is monitored by GPS-assisted piloting software which allows real-time location
tracking. evriMED™ digital data are combined with remaining pill-count to monitor patient’s
adherence to therapy and adjust follow-up on a monthly basis.
Modified strategies
To better assess the impact of specific innovations on cost-effectiveness, we modeled strategies
where DOTS is augmented with individual innovations in a modular approach and where
those same interventions are individually removed from the DrOTS bundle. We made explicit
assumptions regarding how modifications affected diagnosis and treatment outcomes. This
sub-analysis provides insights, though hypothetical, on the cost-effectiveness of using adher-
ence monitoring technologies, GeneXpert™ MTB/RIF and drones independently for tubercu-
losis control in remote African populations.
Decision analysis model
To calculate the ICER of DrOTS, a decision analysis model was designed using TreeAge Soft-
ware (Tree Age Pro 2017, Health Care Edition; Williamstown, USA), and cross-checked
against simplified calculations in R (R Foundation for Statistical Computing, Vienna, Austria).
The model estimates costs, clinical outcomes, and disability-adjusted life years (DALYs) asso-
ciated with DOTS, DrOTS and modified strategies over a 6 months period what corresponds
to a complete treatment course for drug-susceptible pulmonary TB. A simplified representa-
tion of the decision tree is shown in Fig 2.
DrOTS and DOTS model assumptions are detailed and referenced in Table 1. When possi-
ble, assumptions were based on field data collected in Madagascar by authors. In absence of
primary data, Madagascar public health data or published data was used to build the model.
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To account for under-reporting to the NTP and improve external validity for high burden
countries, prevalence of TB in the model population is fixed to 250/100,000 people [1].
According to limited published data on the prevalence of chronic respiratory symptoms in
Fig 2. Decision tree analysis model. Decision tree analysis model comparing both strategies and presenting the study population (blue), TB control strategies (orange),
decision nodes (green) and outcomes (red). Model arms width are proportional to probability scores described in text. DOTS; Directly Observed Therapy, DrOTS;
Drone Observed Therapy System, FN; False negatives, FP; False positives, TN; True negatives, TB; Tuberculosis, TP; True positives.
https://doi.org/10.1371/journal.pone.0235572.g002
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similar Malagasy districts, we estimate that minimally 5% of the screened subjects will present
at least one TB symptom and thus be eligible for sputum testing [27]. We further assume that
95% of symptomatic patients will provide sputum for laboratory testing in both care models
[5]. For modelling purposes, all submitted samples are assumed appropriately tested and all
patients are assumed appropriately started on treatment if found to be infected with TB in
both strategies tree arms.
Confronting available baseline demographic data and reported district TB data to estimated
WHO country incidence suggests that conventional DOTS achieves screening of two-thirds of
symptomatic patients through passive case finding [4, 28, 30, 31]. We assume that 95% of indi-
viduals are screened during DrOTS active case finding systematic community outreach activi-
ties. Sputum smear microscopy and GeneXpert™ MTB/RIF assays sensitivity and specificity
characteristics for diagnosis of active pulmonary disease are obtained from the literature [17,
32]. Active case finding generally results in increased case detection and decreased positivity
rates because of broader testing [37]. Diagnostic assay positivity rates and tests predictive val-
ues are not included in the here presented model.
Drug adherence below the 95% and 90% thresholds is, respectively, associated with at least
8% and 17% of treatment failure [29]. We therefore used the 90% total adherence threshold to
categorically differentiate high adherence (>90% total adherence) and low adherence (<90%
Table 1. Model inputs: Parameters, model assumptions, and sensitivity analyses ranges.
Parameter Model assumptions Range Source, reference
TB prevalence in study population (per 100,000) 250 100–1,000 [1, 4, 28]
Chronic respiratory symptoms prevalence (%) 5 1–25 [27]
Willingness to produce sputum for laboratory testing (%) 95 NA [5]
Laboratory testing of submitted clinical samples (%) 100 NA Model assumption
Enrolment into care following TB diagnosis (%) 100 NA Model assumption
Probability of treatment success, with high adherence (%) 92 NA [29]
Probability of treatment success with low adherence (%) 83 NA [29]
DOTS
Probability of being tested for TB—Passive case finding (%) 66 30–90 [4, 28, 30, 31]
Sensitivity of sputum smear exam (%) 64 NA [32]
Specificity of sputum smear exam (%) 98 NA [32]
Probability of high treatment adherence (%) 60 40–95 Field collected data
DrOTS
Probability of being tested for TB—Active case finding (%) 95 50–99 Model assumption
Sensitivity of GeneXpert™ MTB/RIF (%) 88 NA [17, 32]
Specificity of GeneXpert™ MTB/RIF (%) 98 NA [17, 32]
Probability of high treatment adherence (%) 90 50–99 [11, 33]
Age, life expectancy, DALYs and discount rate
Average age of diagnosis (years) 25 NA [34]
Age of early death due to TB (years) 28 NA [34]
Pre-diagnosis active pulmonary disease duration (months) 6 NA [34]
Treatment duration (months) 6 NA [23, 32]
Life expectancy at birth (years) 63.6 NA [34, 35]
Disability weight due to TB 0.333 NA [35]
Discounting rate (%) 5 NA [36]
DALYs, disability adjusted life years; DOTS, directly observed therapy short course; DrOTS, drone observed therapy system; MTB, Mycobacterium tuberculosis; NA, not
applicable; RIF, rifampicin; TB, tuberculosis.
https://doi.org/10.1371/journal.pone.0235572.t001
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total adherence) patients. Treatment outcomes were identically modeled according to those
thresholds in both arms. Based on primary data collected in TB clinics in the study area, the
probability of being highly adherent under DOTS was found to be 60%. This calculation was
based on surrogate adherence markers which include providers’ reporting, NTP recorded
treatment success rate, and the matching of prescribed doses with the anticipated number of
doses included in a standard 6 months regimen [28]. In the DrOTS arm, where treatment
adherence is supported and measured by evriMED™ devices, no data from Madagascar or
other rural sub-Saharan Africa is yet available. Probability of patients being highly adherent is
estimated to be 90% based on a systematic review on digital adherence monitoring technology
and a large-scale trial in rural Chinese communities [11, 33, 38].
Both DOTS and DrOTS patients testing falsely negative on smear microscopy or GeneX-
pert™ MTB/RIF are expected to self-present to care a second time because of ongoing symp-
toms and be re-tested for TB. TB patients either refusing testing or not being screened go
untreated. For those testing falsely positive, TB treatment is initiated, and costs associated with
TB are included. Costs associated with missed alternative diagnosis, negative health outcomes
and potential medication undesired effects are not considered in the analysis. This model
focuses on prevalent cases but does not take into account incident cases in the study villages
which would occur during the 6 months span or incident cases which would be prevented
because of index cases diagnosis and management. Subjects under 5 years of age are excluded
from the analysis acknowledging the fact that childhood TB diagnosis and management
requires a personalized approach in closer collaboration with centralized healthcare facilities.
Disability adjusted life years
DALYs were chosen as outcome measure of both modelled TB care strategies to ensure com-
parability between TB control strategies [39, 40]. Life expectancy, disease duration and disabil-
ity weights and present-value discounting were considered in the DALYs estimates. Once
patients successfully complete treatment, it is assumed that they subsequently live to full life
expectancy as is the case for those unaffected by disease. Based on published case series and
country-specific data in Madagascar, the average age at diagnosis is estimated at 25 years, total
life expectancy is 63,6 years and the weight index used to calculate pre-fatal health loss attribut-
able to time lived with active TB disease is 0.333 (95% CI: 0.224–0.454) as suggested by the
Global Burden of Disease 2013 study [34, 35]. The duration of symptomatic active pulmonary
disease leading to diagnosis is 6 months and patients going undiagnosed or failing therapy are
assumed to succumb within 3 years [34]. Drug susceptible TB treatment is included in dura-
tion of disease and is assumed to be limited to 6 months. Using the lifetime horizon, a 5% dis-
count rate and these inputs, we calculated DALYs expected due to diagnosis and treatment of
TB and DALYs expected due to untreated TB for both TB care strategies [36, 41].
Costs
Total costs are calculated in USD per TB patient and inflated to 2019 with an annual inflation
rate of 4.9% for expenses and costing data predating the cost analysis [42]. Using field collected
and literature data, a mixed micro and macro costing approach was used to identify costs asso-
ciated with both care models. Common and strategy-specific elements of costs for DOTS and
DrOTS are detailed and referenced in Table 2.
Costs of TB medication, NTP indirect expenses and patient support are the same for both
care models, were estimated based on the WHO’s ‘CHOICE–Unit costs estimate for service
delivery tool’ and were cross validated with NTP officials and TB clinic managers in Madagas-
car [43]. NTP indirect costs include salaries of program managers, coordination and
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equipment at national and regional levels. Patient support includes nutritional aid, transporta-
tion vouchers for medical visits and other in-kind benefits given to TB patients as recom-
mended by national TB guidelines [23]. Costs related to untreated or unsuccessfully treated
TB in Madagascar were estimated using LMIC-specific costing data from a systematic review
[45]. Those costs include repeated medical consultations or hospitalizations, therapeutic inter-
ventions and adverse events management associated with incorrectly diagnosed non-TB respi-
ratory conditions and potential need for laboratory screening of multidrug-resistant TB
(MDR-TB) due to repeated inadequate management. Unit cost of sputum smear microscopy
used for initial diagnosis in DOTS and for per-treatment control testing in both care models is
based on literature and WHO assessment [43, 44]. For patients initially testing falsely negative,
costs associated with laboratory diagnosis are doubled in the cost analysis accounting for
repeated consultation with persistent symptomatology.
DOTS specific costs include those associated with outpatient visit, facility-based human
resources and laboratory microscopy initial diagnosis. The operation costs of district (CDT)
and lower levels facilities involved in TB patient care are used to calculate outpatient visits
costs. Human resources include salaries of physician, laboratory technician and nursing per-
sonnel adjusted to the number of anticipated interactions a TB patient has with these respec-
tive providers over one TB episode treatment course. Costs associated with the necessity for
patients to relocate near treatment center for the 2-months initial treatment phase are not
Table 2. DOTS and DrOTS elements of costs.
Cost element Cost
(USD)
Source, reference
Drugs for treatment of drug-susceptible TB 39.79 [43]
Patient support costs 41.89 [43]
NTP indirect program costs 14.66 [43]
NTP human resources costs 14.66 [43]
Unit cost sputum smear microscopy 2.25 [43, 44]
Untreated TB costs 209.00 [45]
Madagascar GDP 460.73 [46, 47]
WHO willingness to pay threshold 1,382.19 [39, 46]
DOTS
Cost per outpatient visit 0.95 [43]
DOTS human resources 0.52 Field collected data
DrOTS
Drone system start-up cost annualized over a 5-year time period See Table 3 Field collected data, [8, 18,
44]
Drone specific maintenance cost See Table 3 Field collected data
Cost per round trip drone flight 1.52 Field collected data
GeneXpert MTB/RIF acquisition annualized over a 5-year time
period
6,039.26 Field collected data
Unit cost GeneXpert™ MTB/RIF testing 15.87 [44]
evriMED™ device acquisition annualized over a 5-year time period 3,900.41 Field collected data
DrOTS human resources 11.65 Field collected data
Cost per interaction with CHW 0.50 Field collected data
CHW, Community health worker; DOTS, directly observed therapy short course; DrOTS, drone observed therapy
system; GDP, gross domestic product; MTB, Mycobacterium tuberculosis; NTP; national tuberculosis control
programme; RIF, rifampicin; TB, tuberculosis; USD, United States dollars.
https://doi.org/10.1371/journal.pone.0235572.t002
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included in the analysis since these are assumed by patients and families and this CEA is per-
formed from a healthcare system perspective.
In DrOTS, start-up costs are associated with acquisition of innovative technologies including
bi-directional drone delivery systems, GeneXpert™ MTB/RIF molecular diagnostics machine,
evriMED™ adherence monitoring devices, and the necessary associated communication technolo-
gies and data management systems. Beyond procurement, start-up costs also include initial per-
sonnel training. Start-up costs are annualized over a five-year period as recommended by WHO
guidelines [39]. Table 3 further breaks down the start-up and maintenance costs specifically asso-
ciated with the bi-directional drone transportation program. These budgetary data were collected
from project-specific programmatic planning documents and reports, purchase records, and tax
receipts for drones and other supplies. Drone acquisition, batteries, power supplies and chargers
are those paid by Madagascar project implementers at onset in 2017. Costs associated with com-
puters include computers for all involved parties including technology experts, program manage-
ment and field teams. Biosafety sample transportation materials represent mandatory UN3373
packaging for clinical samples transportation [26]. Packaging, shipment, taxes and customs fees
are applied to all necessary materials unavailable in Madagascar. Other DrOTS specific costs
include costs per outpatient diagnosis and per-treatment interactions with the CHW and addi-
tional human resources supporting field active case finding and drone operations.
For routine operations, specialized personnel are trained for the operation and mainte-
nance of drones, whereas TB nurses and CHW are trained to safely ensure drugs or medical
Table 3. Detailed costs associated with start-up and maintenance of DrOTS.
Component Cost (USD) Source
Total Annualized
Start-up costs
Technology procurement
Drones 237,539 54,869 Field collected data
Batteries 27,229 6,290 Field collected data
Power supply and charger 4,780 1,104 Field collected data
Computers 83,333 19,250 Field collected data
Information technologies and communications 26,118 6033 Field collected data
Packaging and shipment 7,170 1,656 Field collected data
Taxes and customs 356,296 82,304 Field collected data
Biosafety sample transport material 28,200 6,514 Field collected data
Training
CHW 33,391 7,713 Field collected data
NTP personnel 27,838 6,430 Field collected data
Specialized drone personnel 42,910 9,912 Field collected data
Server acquisition 74783 17275 Field collected data
Flight software development and maintenance 61772 14269 Field collected data
Mobile phones 50,000 11,550 Field collected data
Maintenance costs Yearly
Internet connection NA 5,612 Field collected data
Server maintenance NA 2,309 Field collected data
Database maintenance NA 1,251 Field collected data
Insurance NA 26,967 Field collected data
Drones maintenance & storage NA 36,141 Field collected data
CHW, Community health worker; NTP, National Tuberculosis Control Program
https://doi.org/10.1371/journal.pone.0235572.t003
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supplies and clinical samples are respectively extracted and loaded in the drones. For involved
NTP personnel and drone technicians, training occurs upon program launching and after 6
and 12 months of operations. At village level, CHW get intermittent training courses on TB
and appropriate drone usage every four months. Fixed annual operation costs of the drone
program include vehicle maintenance, flight insurance and storage. For cost associated with
drone flight, we only included those associated with electricity for battery charging. Although
flight purposes can be combined in the case were multiple TB patients are cared for in the
same village, this potential economy of scale is inconsistent and thus not considered in this
analysis. To ensure optimal communication, capacity to request drone transportation and
coordination of return flights, CHW are provided with phones. In DrOTS, the cost of GeneX-
pert™ MTB/RIF cartridge are those associated with initial TB diagnosis.
Patients diagnosed with TB in both care models are systematically tested for HIV according
to national TB guidelines [23]. Since prevalence of HIV-TB co-infection in Madagascar is less
than 1%, costs related to HIV testing and management are not accounted for [4, 48]. Similarly,
costs associated with hospitalization, longer treatment course and drug adverse events man-
agement in MDR-TB treatment are excluded since this represents less than 1% of cases in
Madagascar and has never been diagnosed in the study area [4].
According to the World Bank and WolrdData.info, which compiles composite data from
the World Bank and the International Monetary Fund, Madagascar’s annual gross domestic
product (GDP) per capita and average annual income were respectively $460.73 USD and
$510 USD in 2018 [46, 49]. Multiple cost-effectiveness thresholds have been proposed to assess
and prioritize interventions in the health sector. For this analysis, ICER values of three times
Madagascar’s per capita GDP ($1382.19), and one time per capita GDP ($460.73) were consid-
ered cost-effective, and very cost-effective, respectively [39, 50].
DALY, costs and the incremental cost of DrOTS over DOTS is calculated as follows:
DALY ¼ ðLif e expectancy at birth   Age at deathÞ þ ððAge at death
  Age at diagnosis of diseaseÞ X ðDisability weightÞÞ
D DALY averted ¼ ðDALYs expected with DOTSÞ
  ðDALYs expected with DrOTSÞ; taking into account dif f erences in diagnostic and treatment success:
DCosts ¼ ðNet cost of DrOTSÞ   ðNet cost of DOTSÞ
ICER ¼ D Costs=D DALY averted
Modified strategies
To further assess the specific impact of digital adherence monitoring technology, laboratory
diagnostics performance and aerial transportation systems on cost-effectiveness of DrOTS, we
built modified strategies models. Specifically, we assessed the cost and impact of evriMED™
devices for adherence, GeneXpert MTB/RIF for diagnosis accuracy, and drones to support
CHW community case finding by adding each to the DOTS tree in turn. Similarly, we assessed
the specific contribution of those interventions to the cost and impact of DrOTS by removing
each from the DrOTS tree in turn.
Sensitivity analyses
To assess the impact of uncertainty in the value of key input variables, one-way sensitivity anal-
yses were performed across plausible ranges (Table 1). TB prevalence, prevalence of TB-com-
patible symptoms in target communities, probability of being tested in both care models,
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probability of being highly adherent to therapy in both care models and DrOTS start-up costs
were the inputs for which sensitivity analyses were performed. For a subset of those inputs, val-
ues beyond Madagascar’s plausibility ranges were analyzed to increase external validity. For
example, TB prevalence sensitivity analysis was performed between 100 and 1,000 cases per
100,000 to include Madagascar reported notification rates and that of other lower or high bur-
den countries [1, 4].
Results
Program service quantity
The DOTS intervention strategy reached two-thirds of the population presenting chronic
respiratory symptoms and 95%of those accepted to produce a sample for testing using smear
microscopy. DOTS implementation in the study populations hence led to TB testing for 6,333
presumptive TB patients. Of these, 276 were confirmed to have active TB disease and enrolled
into care (Table 4).
The DrOTS intervention strategy reached 95% of the symptomatic patients for GeneXpert
MTB/RIF testing, with 9,025 patients being tested for and 445 being diagnosed and enrolled
into care. This represents a 61.2% (95% CI 58.1–65.2, p<0.05) increase in case finding and
treatment initiation over DOTS.
DOTS led to 244 (88.4%) successfully treated cases and 32 (11.6%) treatment failure cases.
With the implementation of digital adherence monitoring technologies, those outcomes were
respectively 405 (91.0%) and 40 (9.0%) in DrOTS. This represents a 2.6% (95% CI -1.8–7.5,
p = 0.47) increase in successful outcomes.
Of the 500 prevalent TB cases in the modeled 200,000 population, DOTS and DrOTS, led to
256 (51.3%) and 95 (19.0%) TB-related deaths, respectively (p<0.05). The decision analysis
tree model indicates that most of this difference was due to the different case-finding and treat-
ment initiation strategies in DrOTS.
In absence of any intervention in the study population, TB was calculated to account for
7,949 DALYs. Considering an average age of 25 years at disease onset, a life expectancy of 63.6
years and a disability weight of 0.333, DOTS and DrOTS were respectively associated with a
total of 4,157 and 1,643 DALYs at population level (Table 4). This corresponds to an average
8.3 and 3.3 DALYs per TB patient in the population and an incremental effect of 2,514 DALYs
averted (4,157 DALYs for DOTS minus 1,643 DALYs for DrOTS) (p<0.05).
The net costs associated with DOTS and DrOTS implementation in the 200,000 population
were respectively calculated to be $141,132 and $586,101 (Table 4). Net costs associated with
initial case finding, diagnosis and clinical management per TB patient were calculated for both
care models. The costs common to DOTS and DrOTS were $111. DOTS-specific additional
costs were $29 for a total combined cost per TB patient of $140. DrOTS specific costs per
patients were $837 for a total combined cost per TB patient of $948. When accounting for
costs associated with undiagnosed TB and TB testing of symptomatic non-TB patients, DOTS
Table 4. Projected outcomes and cost-effectiveness of DOTS and DrOTS for TB control in a 200,000-population remote district of Madagascar.
Strategy Diagnosed TB
cases
Deaths due to active
TB
DALYS
averted
Net cost
($USD)
Cost per TB patient
($USD)
Incremental cost per additional active TB
case diagnosed
ICER
DOTS 276 256 3,792 141,132 282 NA NA
DrOTS 445 95 6,306 586,101 1,172 2,631 177
DOTS, directly observed therapy short course; DrOTS, drone observed therapy system; ICER, Incremental cost effectiveness ratio; TB, tuberculosis.
https://doi.org/10.1371/journal.pone.0235572.t004
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had a cost of $282 per TB patient in the total population. This number increased to $1,172 in
DrOTS. The incremental cost per additional TB patient diagnosed in DrOTS was 2,631$.
DrOTS has an ICER value of $177 per DALY averted compared to DOTS for diagnosis and
treatment of TB. This represents the incremental cost of DrOTS over DOTS (i.e. DrOTS inter-
vention net cost of $586,101 minus DOTS intervention net cost of $141,132) divided by the
difference in DALYs averted between both strategies (i.e. 6,306 DALYs averted in DrOTS
minus 3,792 DALYs averted in DOTS).
Drones, evriMED™ and GeneXpert™ MTB/RIF modified strategies models
Case finding, treatment outcomes, costs and DALYs were further compared between DOTS,
DrOTS and six additional distinct modified strategies integrating various components of
the DrOTS bundle. evriMED™, GeneXpert™ MTB/RIF and drones were differentially added to
the standard of care DOTS model to assess the individual impact of those interventions on dis-
ease control and cost-effectiveness. Similarly, those interventions were differentially removed
from the DrOTS model to assess their individual contribution to the bundle impact and cost-
effectiveness. Table 5 presents outcomes for all strategies in cost-effectiveness incremental
order.
Given that drones allow for sample transportation and facilitated access to diagnosis facility,
their impact on the decision tree is represented by increased probability of being tested for TB.
Although CHW are present in villages within DOTS, the model assumption is that this alone
doesn’t correlate to higher probabilities of being tested for TB given the transportation impedi-
ments to access to diagnostic laboratories. Adding drone-supported outreach case finding to
DOTS yielded an additional 2,692 (41.6% increase) patients for TB testing and 117 (42.3%
increase) TB case notifications. Even without altering diagnostic testing sensitivity with Gen-
eXpert™ MTB/RIF implementation, drone-supported outreach activities led to an increase in
case finding. The ICER of this strategy over conventional DOTS was measured to be 222 and
the net cost per additional TB patient diagnosed was $2,631. Given the increased sensitivity of
GeneXpert™ MTB/RIF for diagnosis of active TB disease, replacing smear microscopy by
molecular diagnostic in DOTS led to an additional 36 (13.0%) TB patients diagnosed for an
ICER of $115 over DOTS. Purely increasing treatment adherence with evriMED™ in DOTS led
to 7 (2.9%) additional patients successfully completing therapy and averted TB-related deaths
for an ICER of $33. Among all three innovative strategies, increasing case finding using drones
had the highest related number of DALYs averted but came at the highest price.
Removing drone-supported CHW outreach case finding from DrOTS led to a reduction of
133 (29.9%) TB notifications and a 121 (56.0%) increase in TB-related deaths. The ICER of
DrOTS decreased from $177 to $94 by doing so. Drones were found to be the technology most
significantly contributing to DrOTS net costs and ICER. Linking DrOTS to conventional
microscopy by removing GeneXpert™ MTB/RIF from the intervention bundle led to 52
(11.7%) fewer TB notifications and increased the intervention ICER from $177 to $193. Simi-
larly Linking DrOTS to conventional adherence monitoring led to 8 (2.0%) fewer patients suc-
cessfully completing therapy and averted TB-related deaths for an ICER increase from $177 to
$190. Both “DrOTS without GeneXpert™ MTB/RIF” and “DrOTS without evriMED™ scenarios
showed that bridging DrOTS to conventional diagnostics or digital adherence monitoring
technology came at a lower net cost but had a higher ICER.
As presented in Table 5, incrementally adding interventions to strategy bundles did not
always correlate to increased cumulative costs per TB patients diagnosed and ICER. For exam-
ple, implementing DrOTS without GeneXpert MTB/RIF™ represented an economy of $197
per additional TB patients diagnosed and still lead to an increase in ICER of $3 over the
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previous best strategy (DrOTS without everiMED™). Implementing DOTS with drones proved
to be the strategy with the most unfavorable ICER at $222.
Sensitivity analyses and cost-effectiveness thresholds
Sensitivity analyses were performed around model input variables with a higher level of uncer-
tainty (Fig 3). Decreasing TB treatment adherence was shown to have a significant detrimental
effect on DrOTS ICER with costs per averted DALYs reaching $536.94 when treatment high
adherence rate is reduced to 50%. DrOTS ICER was also show to be heavily dependent on case
finding effectiveness and probability of being tested with the ICER increasing to 497.75 USD
per DALY averted when the probability of being tested within DrOTS dropped to 70%. The
ICER of DrOTS over DOTS ranged between 49.95 and 443.44 USD per DALY averted for TB
prevalence rates in the populations respectively varying between 100 and 1,000 per 100,000
population. DrOTS initial costs had a smaller effect than other factors on the ICER between
half ($530,677.92) and twice ($2,122,711.66) the costs associated with the base case scenario,
DrOTS ICER varied from 131.21 and 280.90 USD per DALY averted.
Using model assumption values, DrOTS and all modified strategies’ ICER compared to
DOTS were lower than one annual GDP per capita willingness to pay threshold of $460.73.
For all selected input variable plausibility ranges included in the sensitivity analysis, the ICER
also remained below this threshold. To reach this health system willingness to pay threshold,
TB prevalence had drop to 96/100,000 population what represents a 58.8% decrease from
Madagascar’s current rate. Similarly, the prevalence of TB compatible symptoms in the study
population had to increase to 38.5% for DrOTS to cross the willingness to pay threshold
because of costs associated with testing of non-TB patients. Only by increasing the initial costs
associated to DROTS by 3.8 times to a total of 4,033,152$ did the model confirm an ICER of
460.73 for DrOTS. When assessing specific DOTS-related input variables, the probability of
being tested had to increase to 93.4% for DrOTS to reach the 460.73 ICER threshold. Even
Table 5. Cost-effectiveness of DOTS, DrOTS and modified strategies for TB control in a 200,000-population remote district of Madagascar.
Strategy Diagnosed
TB cases
Deaths due
to active TB
DALYS
averted
Net cost
($USD)
Cost per TB
patient
($USD)
ICER over DOTS
($USD / DALY
averted)
Cumulative incremental cost
per additional active TB case
diagnosed (USD)
Cumulative ICER
($USD / DALY
averted)
DOTS 276 256 3,792 141,132 282 N/A N/A N/A
DOTS with
evriMED™
276 249 3,908 145,032 290 34 8 34
DrOTS without
drones
312 216 4,425 200,545 401 94 111 60
DOTS with
GeneXpert MTB/
RIF™
312 224 4,294 198,751 398 115 -4 21
DrOTS 445 95 6,306 586,101 1,172 177 775 62
DrOTS without
evriMED™
445 107 6,120 582,201 1,164 190 -8 13
DrOTS without
GeneXpert MTB/
RIF™
393 142 5,569 483,943 968 193 -197 3
DOTS with
Drones
393 153 5,404 499,323 999 222 31 29
Strategy bundles outcomes for all in cost-effectiveness incremental order. DOTS, directly observed therapy short course; DrOTS, drone observed therapy system; ICER,
Incremental cost effectiveness ratio; TB, tuberculosis
https://doi.org/10.1371/journal.pone.0235572.t005
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with a probability of being highly adherent of 100% within DOTS, the ICER of DrOTS was
still 193.26. For DrOTS, the probability of being tested and of being highly adherent to therapy
respectively had to drop to 71.1% and 52.2% for the intervention to reach the threshold ICER.
Discussion
In this study, we leveraged primary costing, operational and impact data from the DrOTS pro-
gram in remote Madagascar to build a modeled CEA comparing this novel approach to DOTS
standard of care. We show that a bundle of innovative interventions for TB control including
drones to transport sputum samples and medication, evriMED™ digital adherence monitoring
technology and GeneXpert™ MTB/RIF is cost effective at an ICER of 177 USD per DALY
averted. This is less than the annual GDP per capita which is proposed as a very cost-effective
threshold.
The modeled CEA suggests that linking drones to improved laboratory diagnostics and dig-
ital adherence monitoring technology is essential to further increase cost-effectiveness. Simi-
larly, implementing drones within a standard of care DOTS program was shown to improve
disease control but at a higher ICER than any other approach (ICER = $222 USD per DALY
averted).
Sensitivity analysis further shows that at the low willingness to pay threshold of Madagas-
car’s one GDP per capita ($ 460.73 USD) can still be met in lower TB prevalence settings and
for higher drone program initial acquisition costs. This suggests favorable cost-effectiveness
ratios in other high burden countries with different disease epidemiology and economic reali-
ties. To our knowledge, using TB control in remote Madagascar, this study is the first study to
Fig 3. Incremental cost-effectiveness ratio of DrOTS over DOTS–sensitivity analysis. Sensitivity analysis around key input variables of DrOTS versus DOTS
incremental cost effectiveness ratio analysis.
https://doi.org/10.1371/journal.pone.0235572.g003
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present a cost effectiveness evaluation of bi-directional drone transportation in the health care
sector. It provides reliable and timely data which donors, governments and in-country imple-
mentors should consider in order to guide programs design and resources allocation. It also
sets a benchmark for future programs drone technology acquisition net costs and intervention
related averted DALYs. Our study design permits comparison of the impact on standardized
TB indicators, the costs and ICER of drones with other diagnostic and adherence increasing
interventions with which the TB community is familiar and for which a more significant bur-
den of medical and economic literature is available.
The market for drone technology is currently evolving at unprecedented speed. Our costing
analysis is based on technology initial acquisition costs for the DrOTS project and represents a
current best estimate. Prices and discounting rates for multiple elements of the DrOTS inter-
vention strategy will rapidly evolve in time as the market for drones in global health further
takes shape and technologies are deployed at scale.
It should be kept in mind when analysing the presented data that, given the healthcare sys-
tem perspective of this analysis, patients costs and loss of opportunity as well as societal costs
associated with TB disease are not measured. In Madagascar, most of the population lives in
remote villages and survive on subsistence farming. TB incurs catastrophic health expendi-
tures, productivity losses and opportunity costs, for patients. Those should be further explored
to complement this CEA and provide a societal cost perspective. Determining the success of
innovative technologies implementation in healthcare cannot be limited to the evaluation of
their impact on standardized metrics and costs. Though such measures are central to establish-
ing their added value, the success of innovative public health interventions is also contingent
on how those on the receiving end perceive their roll-out. Hence, formal acceptability and cul-
tural perceptions studies should also be performed [51].
This CEA model has several limitations. Our study focuses on case finding and manage-
ment of active pulmonary TB disease. The impact of latent infection, incipient TB, or extrapul-
monary forms of active disease was not measured. Those forms of TB infection either
represent a reservoir or an unmeasured burden of DALYs which were not part of the analysis.
Our model focused on prevalent cases on a six-month intervention period. It did not account
for retreatment, failures and relapses or for the long-term impact on incidence of reducing the
burden of active disease. Although their prevalence is low in Madagascar, the absence of con-
sideration for HIV-coinfections and MDR-TB infections may limit the external validity of our
study for countries where they represent significant public health challenges. As any model,
this study’s CEA tends to simplify many aspects of TB care. For all evaluated strategies, we
assumed systematic testing of submitted samples and enrollment into care for all diagnosed
cases. Those two potential gaps in the TB cascade of care have many determinants but it is
assumed that those gaps would be wider in the DOTS model therefore favourably increasing
the perceived effectiveness of DrOTS over DOTS. Isolating the net effect of drones in a com-
prehensive care model represents another challenge. In this analysis, drones were modeled as a
mean to improve access to TB diagnostics for TB suspects by overcoming the transportation
challenges leading to significant numbers of recognized but untested patients or lost or sam-
ples in remote Madagascar. Their indirect effects such as improved adherence because of faster
medication availability or diagnosis performance because of better conservation and shorter
transit delays of laboratory samples were not calculated but would most likely increase their
perceived added value and ICER.
Significant transportation infrastructures development is unlikely to match the rate at
which drone transportation and network connectivity are expected to penetrate the most
remote places of the world. From a universal health coverage perspective, innovative interven-
tions amenable to a multi-disease approach such as drones are the need of the hour. More
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specifically within TB vertical programs, creative solutions like DrOTS and its components
can support TB control and improve healthcare delivery in resource limited settings. Local reg-
ulations, costs and logistical challenges will determine the adoption of those technologies mov-
ing forward. This study found DrOTS to be a cost-effective intervention in remote
Madagascar and suggests that such approaches may help finding some of the missing millions
of TB cases in LMICs. This adds urgency to the need to overcome the regulatory, policy and
logistical challenges that constrain the adoption of such technologies moving forward.
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